Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors

CONCLUSION: Enhanced sensitivity of BT-474 breast cancer cells to nebivolol and erdafitinib was probably associated with down-regulation of AKT activation. Combined treatment with nebivolol and erdafitinib is a promising strategy for breast cancer treatment.PMID:37097659 | DOI:10.21873/anticanres.16357

Source: Cell Research - April 25, 2023 Category: Cytology Authors: Yu Jin Kim Se-Kyeong Jang Gyeongmi Kim Sung-Eun Hong Chan Sub Park Min-Ki Seong Hyun-Ah Kim Kwang Seok Kim Chun-Ho Kim Ki Soo Park Jungil Hong Hyeon-Ok Jin In-Chul Park Source Type: research